Literature DB >> 33370022

Causes of Death After Neuroendocrine Tumors Diagnosis: A US Population-Based Analysis.

Mohamad Bassam Sonbol1, Anas M Saad2, Miguel Gonzalez-Velez1, Jason Starr3, Thorvardur R Halfdanarson4.   

Abstract

OBJECTIVE: In this study, we aimed to determine the cause of death (COD) after the diagnosis of neuroendocrine tumors (NET).
METHODS: We used the Surveillance, Epidemiology and End Results (SEER) Program to review patients diagnosed with NET during 2000 to 2016. Patients were followed until death, and different CODs were determined.
RESULTS: Of 94,399 patients with NETs, 40.9% died during the study period. During the first year of diagnosis, most deaths were from NETs (73%), followed by other cancers (11.2%) and cardiac diseases (4.6%). After more than 10 years, NET deaths decreased to 24.3%, whereas other cancers and cardiac disease became more common. Neuroendocrine tumors were responsible for 42.8%, 63.4%, and 81.2% of deaths in grade I, grade II, and grade III, respectively. For grade I localized NET, other cancers (22.2%) were the most common COD followed by NET (19.7%), whereas in grade 2 localized NET, NET was COD in 31.1% of cases followed by other cancers (22.4%). In metastatic disease, NET was the most common COD regardless of grade.
CONCLUSIONS: For low-grade localized NET, deaths were mostly secondary to non-NET causes. In contrast, NET is responsible for most of deaths in metastatic NET regardless of grade.
Copyright © 2020 Wolters Kluwer Health, Inc. All rights reserved.

Entities:  

Mesh:

Year:  2021        PMID: 33370022     DOI: 10.1097/MPA.0000000000001723

Source DB:  PubMed          Journal:  Pancreas        ISSN: 0885-3177            Impact factor:   3.327


  3 in total

1.  Development and Validation of Nomogram-Based Prognosis Tools for Patients with Extremity Osteosarcoma: A SEER Population Study.

Authors:  Yingtao Huang; Chenchen Wang; Dadong Tang; Bing Chen; Zhongchao Jiang
Journal:  J Oncol       Date:  2022-05-12       Impact factor: 4.501

2.  Survival and Incidence Patterns of Pancreatic Neuroendocrine Tumors Over the Last 2 Decades: A SEER Database Analysis.

Authors:  Mohamad Bassam Sonbol; Gina L Mazza; Lanyu Mi; Thomas Oliver; Jason Starr; Hallbera Gudmundsdottir; Sean P Cleary; Timothy Hobday; Thorvardur R Halfdanarson
Journal:  Oncologist       Date:  2022-07-05       Impact factor: 5.837

3.  Epidemiologic Trends of and Factors Associated With Overall Survival for Patients With Gastroenteropancreatic Neuroendocrine Tumors in the United States.

Authors:  Zihan Xu; Li Wang; Shuang Dai; Mingjing Chen; Feng Li; Jianguo Sun; Feng Luo
Journal:  JAMA Netw Open       Date:  2021-09-01
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.